NSCLC Workflows: Steps Adding to TAT

(1:9)

NSCLC Workflows: TAT Considerations \u0026 Guidelines

(2:4)

NSCLC Workflows: Tissue Stakeholder Considerations

(56)

NSCLC Workflows: Maximization of Small Biopsies

(1:32)

Actionable Results and Turnaround Time Indicators for NSCLC Workflows

(44:8)

NSCLC Workflows: TAT Specimen Tracking

(1:13)

NSCLC Workflows: Separate Fragments \u0026 Cut Unstained Slides

(1:3)

NSCLC Workflows: Fixative \u0026 Fixation Time

(1:8)

NSCLC Workflows: Plan for Reflex Testing

(33)

NSCLC Workflows: Tumor Enrichment

(32)

NSCLC Workflows: Assessing Tumor Content

(48)

Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC

(44:25)

Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic Landscape

(44:56)

Unlocking the Power of Genomic Testing in NSCLC: Implementing Personalized Therapy to Impact Outcome

(30:42)

Best Practices in Biomarker Testing for NSCLC Virtual Summit: Tissue Acquisition and Processing

(1:21:52)

Case Study Highlights: CAD's Impact on Lung Cancer Reporting and Streamlined Workflow

(47)

One workflow - endless options: NGS workflow solutions

(23:46)

Recent approvals in the NSCLC treatment landscape

(1:56)

Best Practices in Biomarker Testing for NSCLC Virtual Summit: Ordering and Turnaround Time

(1:38:50)

Tracy Stockley - Variant detection in cell-free DNA from NSCLC using NGS

(46:47)